Kara 360-514-3940
Jasmine 360-514-2154
Chris 360-514-6499

The oncologists at the PeaceHealth Southwest Cancer Center serve as investigators in clinical trials, sponsored by the National Cancer Institute, to advance the understanding and treatment of cancer. When applicable, you may be offered participation in one of these trials. This is entirely optional. For more information read our Frequently Asked Questions.


  • A071701 Genomically-Guided Treatment Trial in Brain Metastases from any solid tumor - central screening for alteration in CDK pathway, P13K/AKT/mTOR pathway, and NTRK/ROS1 translocation.


  • A011401 Breast Cancer WEight Loss Study (BWEL Study):  Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
  • A011502 Aspirin in Preventing Recurrence of Cancer in Patients with HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
  • A171601   A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
  • A221505 Hypofractionated Radiation Therapy after Mastectomy in Preventing recurrence in Patients with Stage IIa-IIIa breast cancer
  • NRG-BR003 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or Without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
  • NRG-BR004   A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First Line HER2-Positive Metastatic Breast Cancer
  • EA1131 Platinum Based Chemotherapy or Capecitabine in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
  • EAZ171 Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy Induced Peripheral Neuropathy in African American Women with stage I-III breast cancer
  • S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
  • S1501 Carvedilol in Preventing Cardiac Toxicity in Patients with Metastatic HER-2-Positive Breast Cancer
  • S1703  Serum Tumor marker Directed Disease Monitoring in patients with Hormone Receptor positive HER2 Negative Metastatic Breast Cancer
  • URCC-18007 Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue in stage I-III breast cancer survivors


  • A021502 Combination Chemotherapy with or Without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • A021602    Cabozantinib S-malate in Treating Patients with Neuroendocrine Tumors previously Treated with Everolimus that are locally advanced, metastatic or cannot be removed by surgery
  • A021703 Randomized Double Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
  • EA2165 Randomized Phase II Study of Nivolumab after combined modality Therapy (CMT) in High Risk Anal Cancer
  • EAQ162CD Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal cancer Treated with Curative Intent
  • GI004  Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
  • S0820 Adenoma and Second Primary Prevention Trial
  • U16092  Phase II Study of Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy
  • NCT00493883   Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors (PHSW only)
  • S1613 A Randomized Phase II Study of Trastuzumab and Pertuzumab compared to Cetuximab and Irinotecan in Advanced/Metastatic Colorectal Cancer with HER2 Amplification


  • A031501 Pembrolizumab in Treating Patients with Locally Advanced Bladder Cancer
  • A031702 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers
  • A031704 PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal cell cancer
  • AGCT1531 Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors  
  • SWOG S1500 Cabozantinib S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients with Locally Advanced or Metastatic Kidney Cancer
  • SWOG S1815  Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers
  • NCT01226004   Multi-Institutional Registry for Prostate Cancer Radiosurgery- (PHSW only)


  • AGCT1531 A Phase III Study of Active surveillance for low risk and a Randomized Trial of Carboplatin vs. Cisplatin for standard Risk Pediatric and Adult Patients with Germ Cell Tumors <50 years of age
  • GOG0263 Radiation Therapy with or Without Chemotherapy in Patients with Stage I or Stage IIA Cervical Cancer Who Previously Underwent Surgery
  • GOG0279  Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients with Locally Advanced Squamous Cell Cancer of the Vulva
  • GY019 A Randomized Phase III, Two-arm trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole monotherapy in Patients with Stage II-IV, Primary Low grade Serous Carcinoma of the Ovary or Peritoneum

Head & Neck 

  • EA3161 A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in patients with Locally Advanced, Intermediate Risk HPV Positive Oropharyngeal Cancer
  • RTOG R1008 A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors (PHSW only)


  • A151216 Adjuvant Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
  • A081105 Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
  • E4512 Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • A221504 Naloxegol in Treating Patients with Stage IIIB-IV Non-small Cell Lung Cancer
  • LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
  • EA5163 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis


  • A041501 A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
  • A041701  A Randomized Phase II/III Study of Conventional chemotherapy +/- Uproleselan in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction chemotherapy
  • A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
  • ACCL16N1CD Cancer Care Delivery in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia
  • EA9161 A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
  • S1712  Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating patients with Chronic Myeloid Leukemia


  • A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in patients with relapsed or refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype
  • A051701 Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas
  • EA4151 Rituximab with or Without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
  • E4412  A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
  • S1826    A Phase III, randomized study of Nivolumab plus AVD or Brentuximab Vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma

Melanoma & Skin

  • EA6134 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma
  • S1616 Ipilimumab With or Without Nivolumab in Treating Patients with Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery  
  • S1801 A Phase II Randomized Study of Adjuvant Vs. Neoadjuvant MK-3475 (Pembrolizumab) for clinically Detectable Stage III-IV High Risk Melanoma
  • A091605  A Randomized Phase II Study of anti-PD1 antibody (Pembrolizumab) alone versus anti-PD1 antibody plus stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma
  • A091802   Phase II Randomized trial of Avelumab Plus Cetuximab versus Avelumab alone in advanced cutaneous squamous cell carcinoma of the skin
  • EA6174  STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III trial

Multiple Myeloma

  • A061202  A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy and Proteasome Inhibitor Based Therapy
  • EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma


  • ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) (age 40 and under)
  • S1701  A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma